The muscular dystrophies are a diverse group of genetic disorders without an effective treatment. Because they are caused by mutations in various genes, the most direct way to treat them involves correcting the underlying gene defect (ie, gene therapy). Such a gene therapy approach involves delivering a therapeutic gene cassette to essentially all the muscles of the body in a safe and efficacious manner. The authors describe gene delivery methods using vectors derived from adeno-associated virus that are showing great promise in preclinical studies for treatment of Duchenne muscular dystrophy. It is hoped that variations on these methods might be applicable for most, if not all, of the different types of muscular dystrophy.
Muir LA, Chamberlain JSEmerging strategies for cell and gene therapy of the muscular dystrophies . Expert Rev Mol Med. 2009; 11:e18.
3.
Monaco AP, Bertelson CJ, Liechti-Gallati S., et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2:90-95.
4.
Baumbach LL, Chamberlain JS, Ward PA, et al. Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology. 1989;39:465-474.
5.
England SB, Nicholson LV, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343:180-182.
6.
Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet. 1995 ;4:1251-1258.
7.
Crawford GE, Faulkner JA, Crosbie RH, et al. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol. 2000;150(6): 1399-1410.
8.
Harper SQ, Hauser MA, DelloRusso C., et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002 ;8(3):253-261.
9.
Wang B., Li J., Xiao X.Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A. 2000;97(25):13714-13719.
10.
Sakamoto M., Yuasa K., Yoshimura M., et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun. 2002; 293(4):1265-1272.
11.
Hoffman EP, Brown RH Jr, Kunkel LMDystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51:919-928.
12.
Koenig M., Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509-517.
13.
Abmayr S., Chamberlain J.The structure and function of dystrophin. In: Winder SJ, ed. Molecular Mechanisms of Muscular Dystrophies. Austin, TX: Landes Biosciences; 2006: 14-34.
14.
Cox GA, Phelps SF, Chapman VM, Chamberlain JSNew mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin . Nat Genet. 1993;4:87-93.
15.
Brooks SV, Faulkner JAContractile properties of skeletal muscles from young, adult and aged mice . J Physiol (Lond). 1988; 404:71-82.
16.
Campbell KPThree muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell. 1995;80:675-679.
17.
Petrof BJ, Shrager JB, Stedman HH, et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993;90:3710-3714.
18.
Henry MD, Campbell KPAn extracellular matrix receptor linked to the cytoskeleton. Curr Opin Cell Biol. 1996;8:625-631.
19.
Ohlendieck K., Campbell KPDystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J Cell Biol. 1991;115:1685-1694.
20.
Chamberlain JS, Rando TA, eds. Duchenne Muscular Dystrophy: Advances in Therapeutics . New York, NY: Taylor and Francis ; 2006.
21.
Im WB, Phelps SF, Copen EH, et al. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet. 1996;5(8):1149-1153.
22.
Valentine BA , Winand NJ, Pradhan D., et al. Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review. Am J Med Genet. 1992;42:352-356.
23.
Cox GA, Cole NM, Matsumura K., et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature. 1993;364(6439):725-729.
24.
Stedman HH, Sweeney HL, Shrager JB, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 1991 ;352:536-539.
25.
Brooks SV, Faulkner JASkeletal muscle weakness in old age: underlying mechanisms. Med Sci Sports Exerc. 1994;26(4): 432-439.
26.
DelloRusso C., Crawford R., Chamberlain J., Brooks S.Tibialis anterior muscles of mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil. 2001;22: 467-475.
27.
Lynch GS, Hinkle RT, Chamberlain JS, et al. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol. 2001;535(pt 2):591-600.
28.
Chamberlain JS, Metzger J., Reyes M., et al. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 2007;21:2195-2204.
29.
Banks GB, Chamberlain JSThe value of mammalian models for Duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol. 2008;84:431-453.
30.
Rafael JA, Sunada Y., Cole NM, et al. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Hum Mol Genet. 1994;3(10):1725-1733.
Rutledge EA , Halbert CL, Russell DWInfectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol. 1998;72(1):309-319.
33.
Xiao W., Chirmule N., Berta SC, et al. Gene therapy vectors based on adeno-associated virus type 1 . J Virol. 1999;73(5):3994-4003.
34.
Gao GP, Alvira MR, Wang L., et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99(18):11854-11859.
35.
Halbert CL, Allen JM, Miller ADAdeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors . J Virol. 2001;75(14):6615-6624.
36.
Duan D., Yan Z., Yue Y., et al. Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol . 2001;75(16):7662-7671.
37.
Grimm D., Kay MA, Kleinschmidt JAHelper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther. 2003; 7(6):839-850.
38.
Gregorevic P., Allen JM, Minami E., et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med. 2006;12(7):787-789.
Muzyczka N.Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992;158:97-129.
41.
Muzyczka N., Berns KIParvoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fundamental Virology. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins ; 2001:1089-1122.
42.
Chao H., Liu Y., Rabinowitz J., et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000;2(6):619-623.
Rabinowitz JE, Samulski J.Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol. 1998 ;9(5):470-475.
45.
Nakai H., Yant SR, Storm TA, et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75(15): 6969-6976.
46.
Chamberlain JR , Schwarze U., Wang PR, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science. 2004;303(5661):1198-1201.
47.
Xiao X., Li J., Samulski RJEfficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70(11):8098-8108.
48.
Fisher KJ, Jooss K., Alston J., et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997;3(3): 306-312.
49.
Song S., Morgan M., Ellis T., et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci U S A. 1998; 95(24):14384-14388.
50.
Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999; 5(1):56-63.
51.
Manno CS, Chew AJ, Hutchison S., et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101(8):2963-2972.
52.
Odom GL, Gregorevic P., Chamberlain JSViral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta. 2007; 1772(2):243-262.
53.
Toromanoff A., Cherel Y., Guilbaud M., et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther.2008;16(7):1291-1299.
54.
DelloRusso C., Scott J., Hartigan-O’Connor D., et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci U S A.2002 ;99:12979-12984.
55.
Gilchrist S. , Ontell M., Kochanek S., Clemens P.Immune response to full-length dystrophin delivered to dmd muscle by a high-capacity adenoviral vector. Mol Ther. 2002;6(3):359.
56.
Chen HH, Mack LM, Kelly R., et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A. 1997 ;94:1645-1650.
57.
Gilbert R., Nalbantoglu J., Howell JM, et al. Dystrophin expression in muscle following gene transfer with a fully deleted (‘‘gutted’’) adenovirus is markedly improved by trans-acting adenoviral gene products. Hum Gene Ther. 2001;12(14):1741-1755.
58.
Gregorevic P., Chamberlain JSFunctional enhancement of skeletal muscle by gene transfer. Phys Med Rehabil Clin North Am. 2005;16(4):875-887.
59.
Gregorevic P., Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004;10(8):828-834.
60.
Townsend D. , Blankinship MJ, Allen JM, et al. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure . Mol Ther. 2007;15:1086-1092.
61.
Lai Y., Thomas GD, Yue Y., et al. Dystrophins carrying spectrinlike repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest.2009;119(3):624-635.
Banks GB, Combs AC, Chamberlain JR, Chamberlain JSMolecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Hum Mol Genet . 2008;17(24):3975-3986.
64.
Deconinck N. , Rafael JA, Beckers-Bleukx G., et al. Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse. Neuromuscul Disord. 1998; 8(6):362-370.
65.
Rafael JA, Tinsley JM, Potter AC, et al. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet. 1998;19(1):79-82.
66.
Gilbert R., Nalbantoglu J., Petrof BJ, et al. Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther. 1999;10(8):1299-1310.
67.
Odom GL, Gregorevic P., Allen JM, et al. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice . Mol Ther. 2008;16(9):1539-1545.
68.
Bridges CR, Burkman JM, Malekan R., et al. Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation. Ann Thorac Surg. 2002;73(6):1939-1946.
69.
Su LT, Gopal K., Wang Z., et al. Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector. Circulation. 2005;112(12):1780-1788.
70.
Ohshima S., Shin JH, Yuasa K., et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther.2009;17(1):73-80.
71.
Yue Y., Ghosh A., Long C., et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther. 2008;16(12):1944-1952.
72.
Rodino-Klapac LR, Janssen PM, Montgomery CL, et al. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med. 2007;5(1):45.
73.
Rodino-Klapac LR, Montgomery CL, Bremer WG, et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther.2010;18(1):109-117.
74.
Qiao C., Li J., Zheng H., et al. Hydrodynamic limb vein injection of AAV8 canine myostatin propeptide gene in normal dogs enhances muscle growth. Hum Gene Ther.2009;20(1):1-10.
75.
Gregorevic P., Schultz BR, Allen JM, et al. Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol Ther.2009;17(8): 1427-1433.
76.
Bish LT, Sleeper MM, Brainard B., et al. Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines . Mol Ther. 2008; 16(12):1953-1959.
77.
Mingozzi F., Meulenberg J., Hui DJ, et al. Capsid-specific T-cell responses in humans upon intramuscular administration of an AAV-1 vector expressing LPLs447x transgene. Hum Gene Ther. 2007;18(10):991-992.
78.
Mingozzi F., High KAImmune responses to AAV in clinical trials. Curr Gene Ther . 2007;7(5):316-324.
79.
Mingozzi F., Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood.2009;114(10):2077-2086.
80.
Mendell JR, Rodino-Klapac LR, Rosales-Quintero X., et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol.2009; 66(3):290-297.
81.
Wang Z., Allen JM, Riddell SR, et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther. 2007; 18(1):18-26.
82.
Wang Z., Kuhr CS, Allen JM, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther. 2007;15(6):1160-1166.
83.
Wang Z., Storb R., Lee D., et al. Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther.2010;18(3):617-624.
84.
Goyenvalle A., Babbs A., Powell D., et al. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther.2010;18(1):198-205.
